Infectious disease Archives

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

ngs bioinformatics biomerieux illumina microbiology immunoassay

News and Trends 16 Dec 2015

Global NGS Leader’s Influence in European Bioinformatics Field is Spreading Interest in Microbiomics

BioMérieux (France) is a diagnostics tech company which has partnered with the US Bioinformatics Giant Illumina to produce a novel Microbiological genetics sequencing kit: the bioMérieux EpiSeq. BioMérieux is a worldwide leading provider of diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and reduce risk of hospital […]

December 16, 2015 - 3 minutesmins - By Dani Bancroft

immbio pneumonia vaccine infection heat shock proteins

News and Trends 10 Dec 2015

A New Vaccine Against Pneumonia and Meningitis Reaches Human Trials..

Pneumonia, Meningitis and Sepsis: All these potentially fatal infections could one day be vaccinated against with Cambridge’s ImmBio and their Pneumococcal vaccine, which has now started safety & tolerability trials in the UK. ImmBio is based at the Babraham Institute, a unit of the UK’s Biotechnology & Biological Sciences Research Council (and in our Listed […]

December 10, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 20 Nov 2015

Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

This week we say farewell to Austria and head North-West, across the United Kingdom and land in the Emerald Isle, Ireland, where we arrive at our destination, Dublin. The capital city of Ireland is the home of the very famous Irish dry stout, Trinity College (plus its stunning library) and a nearly 900-year-old cathedral. It is […]

November 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Nov 2015

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna…one of the biggest deals in Biotech today. Moderna is the mRNA therapies companies from Cambridge/Boston (US), most famous for having raised over 900 million dollars in VC money. I met Stephane one and a […]

November 16, 2015 - 1 minutemin - By Philip Hemme

News and Trends 13 Nov 2015

Curetis Molecular Diagnostics IPO Exceeds Expectations

The Southern German Med-tech for infectious disease biotech, Curetis, has sold shares up to a value of €40M, which is 10 million above its initial target, despite a lower ranged Offer price. Curetis have developed a molecular diagnostics system for hospital acquired infections (such as MRSA and Pneumonia). Their Unyvero system is a piece of […]

November 13, 2015 - 2 minutesmins - By Dani Bancroft

seasonal influenza universal vaccine sanofi peptcell seek niaid nihr

News and Trends 12 Nov 2015

Sanofi’s COBRA Research to Tackle the Challenge of A Universal Influenza Vaccine for Winter

Sanofi Pasteur is the infectious disease division of the French Giant Sanofi, responsible for producing 1 Billion vaccine doses each year. Now they are looking to ‘evolve’ the vaccine R&D field, adapting their approach to find a broader spectrum defense against seasonal Influenza strains. However, the UK NIHR and PepTCell are also after the same […]

November 12, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 12 Nov 2015

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

I am still at the mRNA Convention in Berlin…and was invited for a second interview – this time with the ‘RNA People’, battling to be the first to get an mRNA Drug onto the Worldwide Market. I had a chat with Franz-Werner Haas, the Chief Corporate Office of CureVac. We talked a lot about this […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 9 Nov 2015

A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…

Approved drugs can always show bad signs once injected massively. Four physicians from Paris sent a letter to the New England Journal of Medicine to report that Gilead’s Hepatitis C blockbuster drug, Sovaldi, can cause abnormally slower heart rates and risks of Heart Failure… The French Physicians report used data based on 415 patients treated […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Nov 2015

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies. Indeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU […]

November 3, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 28 Oct 2015

Fighting Infection with a Pioneering Arsenal of Med-Tech Inventions from the UK

Bath, in South West England, has a lot more besides its historic beauty…The Jenkins Chemistry lab at the University of Bath has a fair few innovative solutions to the problem of infectious disease detection. Their latest design is a burns dressing which glows when a pathogenic biofilm is detected (as part of the Bacteriosafe Project) […]

October 28, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Oct 2015

Belgian Biotech Seed Investment to Produce Affordable Vaccines for Developing Countries

The Belgian biomanufacturing company Univercells and the Japanese pharmaceutical company Takeda have signed a strategic partnership agreement. Univercells has closed a €3M equity investment with Takeda Ventures to produce affordable vaccines. Univercells provides single-use cost-efficient bioprocess solutions to lead the next generation in biomanufacturing. Under the terms of the agreement, the two biotechs will launch a […]

October 27, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us